Fiona Marshall (pharmacologist)

From Wikipedia the free encyclopedia

For the archaeologist, see Fiona Marshall.

Fiona Marshall
FRS FMedSci
Marshall speaking at the National Institutes of Health 2017 Daly lecture
Born
Fiona Hamilton Marshall
Alma materUniversity of Bath (BSc)
University of Cambridge (PhD)
Scientific career
FieldsDrug discovery
GPCRs
Neuroscience[1][2]
InstitutionsNovartis
Merck & Co.
GlaxoSmithKline
ThesisCholecystokinin/dopamine interactions in the rat basal ganglia (1990)
Doctoral advisorJohn Hughes

Fiona Hamilton Marshall FRS FMedSci is a British pharmacologist, biotech-founder and President of Biomedical Research at Novartis.[3][2][4] She founded and previously served as Chief Scientific Officer at Heptares Therapeutics,[2] which was acquired by the Japanese biopharmaceutical company Sosei, where she served as Vice President.[1] She was elected Fellow of the Academy of Medical Sciences in 2016[5] and the Royal Society in 2021.[6]

Early life and education[edit]

Marshall became interested in biology, chemistry and physics at high school.[7] As a teenager she won a prize at a national physics competition. Marshall graduated with a First class degree in biochemistry from the University of Bath in 1987.[8] She moved to the University of Cambridge for her graduate studies,[9] where she focussed on neuroscience under the supervision of John Hughes.[9] Her doctoral advisor served as director of the University of Cambridge Parke-Davis Research Centre, which inspired Marshall to work in the pharmaceutical industry.[8]

Research and career[edit]

After earning her doctorate Marshall moved to GlaxoSmithKline where she joined the department of neuropharmacology. Marshall worked alongside Patrick Humphrey and Mike Tyers at GlaxoSmithKline. Here she investigated the receptors that are activated by neurotransmitters and microbial metabolites.[10] After only nine years, Marshall was made Head of Molecular Pharmacology in 1999.[8] She eventually moved from the neuropharmacology team to a group working on G protein-coupled receptors.[8] Almost a third of drugs work through these G protein-coupled receptors.[7] She was the first to identify and describe the cloning and structural requirements of the GABAB receptor, a member of the GPCR family. She was headhunted by Millennium Pharmaceuticals and joined as their Director of Molecular Pharmacology in 2000.[8] When her children were young, Marshall took time away from her work in the pharmaceutical Industry to work more flexibly as a consultant..[7]

Working with Malcolm Weir, and together with Christopher Tate and Richard Henderson, Marshall founded Heptares Therapeutics,[11] a spin-out from the Medical Research Council (MRC).[12] Heptares makes use of technologies developed by the Medical Research Council that allow the crystallisation and characterisation of G protein-coupled receptors for drug design.  This included the first crystal structure of the GLP-1 receptor.[13] One of the cancer therapy drug candidates developed by Heptares was licensed to AstraZeneca in 2015. Later that year, Heptares was incorporated into the Japanese bio-pharmaceutical company Sosei.[7][2]

Marshall joined Merck & Co as Head of the UK Discovery Research Centre in 2018. In this capacity she concentrated on diseases of ageing. In 2019 she was made Global Head of Neuroscience   Discovery, where she spent two years before being appointed Senior Vice President of Discovery, Preclinical & Translational Medicine Research.[14] In 2022 she became the President of Biomedical Research at Novartis.[15]

Awards and honours[edit]

Selected publications[edit]

  • Julia H. White; Alan Wise; Martin J. Main; et al. (17 December 1998). "Heterodimerization is required for the formation of a functional GABA(B) receptor". Nature. 396 (6712): 679–82. Bibcode:1998Natur.396..679W. doi:10.1038/25354. ISSN 1476-4687. PMID 9872316. Wikidata Q22008591.
  • Ali Jazayeri; Mathieu Rappas; Alastair J H Brown; et al. (31 May 2017). "Crystal structure of the GLP-1 receptor bound to a peptide agonist". Nature. 546 (7657): 254–258. doi:10.1038/NATURE22800. ISSN 1476-4687. PMID 28562585. Wikidata Q50968563.
  • N. G. Bowery; B. Bettler; W. Froestl; J. P. Gallagher; F. Marshall; M. Raiteri; T. I. Bonner; S. J. Enna (1 June 2002). "International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function". Pharmacological Reviews. 54 (2): 247–264. doi:10.1124/PR.54.2.247. ISSN 0031-6997. PMID 12037141. Wikidata Q34130831.
  • Alan Wise; Steven M Foord; Neil J Fraser; et al. (9 January 2003). "Molecular identification of high and low affinity receptors for nicotinic acid". Journal of Biological Chemistry. 278 (11): 9869–9874. doi:10.1074/JBC.M210695200. ISSN 0021-9258. PMID 12522134. Wikidata Q28202556.
  • Fiona H Marshall; Kenneth A Jones; Klemens Kaupmann; Bernhard Bettler (1 October 1999). "GABAB receptors - the first 7TM heterodimers". Trends in Pharmacological Sciences. 20 (10): 396–399. doi:10.1016/S0165-6147(99)01383-8. ISSN 0165-6147. PMID 10498952. Wikidata Q33739386.

References[edit]

  1. ^ a b Fiona Marshall publications indexed by Google Scholar Edit this at Wikidata
  2. ^ a b c d Fiona Marshall publications from Europe PubMed Central
  3. ^ Fishburn, C. Simone. "Reshaping research at Novartis". BioCentury. Retrieved 12 June 2024.
  4. ^ Carroll, John. "NIBR chief Jay Bradner joins the exodus at Novartis, handing the keys to Fiona Marshall". Endpoints News. Retrieved 1 September 2022.
  5. ^ "Dr Fiona Marshall | The Academy of Medical Sciences". acmedsci.ac.uk.
  6. ^ a b Anon (2021). "Fiona Marshall". royalsociety.org. Royal Society. Retrieved 14 May 2021.
  7. ^ a b c d e "Meet the infocus ambassadors - Fiona Marshall - Innovate UK". innovateuk.blog.gov.uk. Archived from the original on 15 May 2021. Retrieved 14 May 2021.
  8. ^ a b c d e f "Dr Fiona Marshall FMedSci, FBPhS, FRSB: oration". bath.ac.uk. Retrieved 14 May 2021.
  9. ^ a b Marshall, Fiona Hamilton (1990). Cholecystokinin/dopamine interactions in the rat basal ganglia. cam.ac.uk (PhD thesis). University of Cambridge. OCLC 82547258. EThOS uk.bl.ethos.386170.
  10. ^ a b Therapeutics, Heptares. "Heptares Chief Scientific Officer and Co-founder - Dr Fiona Marshall - Elected as a Fellow of the Academy of Medical Sciences". prnewswire.com (Press release). Retrieved 14 May 2021.
  11. ^ Mike, Scialom (19 October 2018). "It's a new day for Sosei Heptares". Cambridge Independent. Retrieved 28 September 2023.
  12. ^ a b "Dr Fiona Marshall". bps.ac.uk.
  13. ^ "Crystal structure of the GLP-1 receptor bound to a peptide agonist | Nature". Nature.
  14. ^ "Fiona Marshall elected a fellow of the Royal Society". msd.com. Retrieved 14 May 2021.
  15. ^ "Novartis Nabs Merck Veteran to Helm BioMedical Institutes". BioSpace. Retrieved 12 June 2024.
  16. ^ "Malcolm Campbell Memorial Prize winners 2015 – RSC Medicinal Chemistry Blog". rsc.org. Retrieved 14 May 2021.
  17. ^ "BPS Vane Medal". bps.ac.uk. British Pharmacological Society.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Fiona_Marshall_(pharmacologist)&oldid=1230039240"